CY1119950T1 - Μη υδατικα μονοφασικα βιοσυμβατα ιξωδη οχηματα και μεθοδοι παρασκευης αυτων - Google Patents

Μη υδατικα μονοφασικα βιοσυμβατα ιξωδη οχηματα και μεθοδοι παρασκευης αυτων

Info

Publication number
CY1119950T1
CY1119950T1 CY20121100281T CY121100281T CY1119950T1 CY 1119950 T1 CY1119950 T1 CY 1119950T1 CY 20121100281 T CY20121100281 T CY 20121100281T CY 121100281 T CY121100281 T CY 121100281T CY 1119950 T1 CY1119950 T1 CY 1119950T1
Authority
CY
Cyprus
Prior art keywords
visual
surfactant
esters
solvent
copolymers
Prior art date
Application number
CY20121100281T
Other languages
English (en)
Inventor
Stephan Berry
Pamela J. Fereira
Houdin Dehnad
Anna Muchnik
Original Assignee
Intarcia Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119950(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intarcia Therapeutics, Inc filed Critical Intarcia Therapeutics, Inc
Publication of CY1119950T1 publication Critical patent/CY1119950T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτεται μη υδατικό μονοφασικό βιοσυμβατό ιξώδες όχημα ικανό να εναιωρήσει επωφελές μέσο και να διανείμει το επωφελές μέσο για παρατεταμένη χρονική περίοδο σε θερμοκρασία σώματος. Το όχημα περιλαμβάνει διαλύτη, επιφανειοδραστικό, και πολυμερές. Ο διαλύτης, το επιφανειοδραστικό και το πολυμερές δεν είναι τα ίδια. Ο διαλύτης είναι λαυρυλική αλκοόλη ή γαλακτικός λαυρυλεστέρας, το επιφανειοδραστικό επιλέγεται από την ομάδα που αποτελείται από εστέρες πολυυδρικών αλκοολών, αιθοξυλιωμένο καστορέλαιο, πολυσορβικά, εστέρες ή αιθέρες κορεσμένων αλκοολών, και συμπολυμερή κατά συστάδες πολυοξυαιθυλενίου-πολυοξυπροπυλενίου, και το πολυμερές επιλέγεται από την ομάδα που αποτελείται από πολυεστέρες, πυρρολιδόνες, εστέρες ή αιθέρες ακόρεστων αλκοολών, και συμπολυμερή κατά συστάδες πολυοξυαιθυλενίου-πολυοξυπροπυλενίου.
CY20121100281T 1999-02-08 2015-05-22 Μη υδατικα μονοφασικα βιοσυμβατα ιξωδη οχηματα και μεθοδοι παρασκευης αυτων CY1119950T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08
EP00913350A EP1152749B1 (en) 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Publications (1)

Publication Number Publication Date
CY1119950T1 true CY1119950T1 (el) 2018-12-12

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100281T CY1119950T1 (el) 1999-02-08 2015-05-22 Μη υδατικα μονοφασικα βιοσυμβατα ιξωδη οχηματα και μεθοδοι παρασκευης αυτων

Country Status (22)

Country Link
EP (2) EP1666026B2 (el)
JP (1) JP4861551B2 (el)
KR (2) KR100858856B1 (el)
CN (1) CN1232244C (el)
AR (1) AR029613A1 (el)
AT (2) ATE322889T1 (el)
AU (1) AU775904B2 (el)
CA (1) CA2361424C (el)
CO (1) CO5140096A1 (el)
CY (1) CY1119950T1 (el)
DE (1) DE60027272T2 (el)
DK (1) DK1666026T4 (el)
ES (2) ES2261190T3 (el)
HK (2) HK1041451B (el)
HU (1) HUP0200202A3 (el)
IL (1) IL144755A0 (el)
NO (1) NO20013861L (el)
NZ (1) NZ513441A (el)
PT (2) PT1152749E (el)
TW (2) TWI292716B (el)
WO (1) WO2000045790A2 (el)
ZA (1) ZA200106443B (el)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004056338A2 (en) * 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
AU2004227985B2 (en) 2003-03-31 2009-04-02 Intarcia Therapeutics, Inc. Osmotic pump with means for dissipating internal pressure
JP2006522133A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012160179A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
ES2617968T3 (es) 2011-05-25 2017-06-20 Novaliq Gmbh Composición farmacéutica para la administración a uñas
CN104023743B (zh) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
KR102171897B1 (ko) 2012-09-12 2020-11-02 노바리크 게엠베하 부분불소화 알칸 조성물
EP3024484B1 (en) 2013-07-23 2018-06-20 Novaliq GmbH Stabilized antibody compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
KR102351816B1 (ko) 2017-04-21 2022-01-17 노바리크 게엠베하 요오드 조성물
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1993009763A1 (en) † 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU6410494A (en) † 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
EP0705097B2 (en) † 1993-06-25 2004-01-14 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
CA2167526A1 (en) † 1993-09-29 1995-04-06 Lina Tormen Taskovich Monoglyceride/lactate ester permeation enhancer
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
CA2224125C (en) * 1995-06-06 2004-09-28 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
US5904935A (en) † 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
RU2177311C2 (ru) † 1995-06-07 2001-12-27 Орто-Макнейл Фармасьютикалз Инк. Трансдермальный пластырь для введения 17-деацетилноргестимата отдельно или в сочетании с эстрогеном
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
WO1998002169A2 (en) † 1996-07-15 1998-01-22 Alza Corporation Novel formulations for the administration of fluoxetine
ES2191834T3 (es) † 1996-10-24 2003-09-16 Alza Corp Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
ES2158611T3 (es) † 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
PT1666026E (pt) 2012-03-15
HUP0200202A2 (hu) 2002-05-29
DK1666026T3 (da) 2012-04-10
DE60027272D1 (de) 2006-05-24
WO2000045790A2 (en) 2000-08-10
ATE322889T1 (de) 2006-04-15
EP1666026B2 (en) 2015-02-25
NO20013861L (no) 2001-09-20
ATE537811T1 (de) 2012-01-15
AU775904B2 (en) 2004-08-19
ES2261190T3 (es) 2006-11-16
EP1152749A2 (en) 2001-11-14
EP1666026A2 (en) 2006-06-07
KR20010101842A (ko) 2001-11-14
HK1041451A1 (en) 2002-07-12
CN1339962A (zh) 2002-03-13
ES2379471T3 (es) 2012-04-26
HK1094528A1 (en) 2007-04-04
KR20080045300A (ko) 2008-05-22
NO20013861D0 (no) 2001-08-08
CA2361424C (en) 2009-04-28
EP1666026B1 (en) 2011-12-21
PT1152749E (pt) 2006-08-31
EP1152749B1 (en) 2006-04-12
KR100858856B1 (ko) 2008-09-17
AR029613A1 (es) 2003-07-10
JP4861551B2 (ja) 2012-01-25
CO5140096A1 (es) 2002-03-22
ES2379471T5 (es) 2015-05-26
CN1232244C (zh) 2005-12-21
EP1666026A3 (en) 2007-08-08
TW200730199A (en) 2007-08-16
NZ513441A (en) 2004-01-30
HK1041451B (zh) 2006-12-01
TWI292716B (en) 2008-01-21
JP2002536315A (ja) 2002-10-29
IL144755A0 (en) 2002-06-30
AU3481600A (en) 2000-08-25
CA2361424A1 (en) 2000-08-10
HUP0200202A3 (en) 2009-08-28
DE60027272T2 (de) 2007-01-25
ZA200106443B (en) 2002-08-06
DK1666026T4 (da) 2015-05-04
WO2000045790A3 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
CY1119950T1 (el) Μη υδατικα μονοφασικα βιοσυμβατα ιξωδη οχηματα και μεθοδοι παρασκευης αυτων
FR2769313B1 (fr) Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
EP1640315A3 (en) System and method of providing a regenerating protective coating in a MEMS device
ATE259217T1 (de) Flüssige zusammensetzungen mit kontrollierter freigabe mit niedrigem initialfreisetzungsstoss des wirkstoffs
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
DE69721481D1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
WO2001091699A3 (en) Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
BR9000976A (pt) Suporte de equipamentos para porta de veiculo automovel,e porta de veiculo automovel
ES2107814T3 (es) Dispositivo de guardar las gafas, sobre todo para su incorporacion en los vehiculos automoviles.
DE60019599D1 (de) 1,2,3,4,5,6,-hexahydroazepino[4,5-b]indole, die arylsulfone an die 9-stellung enthalten
AU2001244289A1 (en) Oxidation dyeing composition for keratinous fibres comprising a 3,5-diamino-pyridine derivative and particular thickening polymer
ES2188697T3 (es) Procedimiento para mejorar la estabilidad transversal en vehiculos automoviles.
ES2122353T3 (es) Hidrogeles hidrofilos, con una alta capacidad de hinchamiento.
ES2158201T3 (es) Alcoxisilacicloalcanos, su procedimiento de preparacion y su utilizacion para la polimerizacion de olefinas.
ATE305934T1 (de) Verfahren zur herstellung von maytansinol
ITTO940104A0 (it) Procedimento per la generazione di impulsi ottici ultracorti.
AU2001280212A1 (en) Monomer composition, polymer obtained therefrom, and ocular lens
AU8021201A (en) Monomer composition, polymer obtained therefrom, and ocular lens
PT1002009E (pt) Transformacao de polimeros expandidos
IT1286140B1 (it) Procedimento e dispositivo per la generazione di impulsi ottici ultracorti.
ES2178631T3 (es) Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
CA2006859A1 (en) Sulfur-containing polymeric polyesters and additive concentrates and lubricating oils containing same
ES2056764T1 (es) Producto para el tratamiento del cabello y procedimiento para su uso.
ATE327279T1 (de) Verfahren zur herstellung aluminiumpulver enthaltender expandierbarer styrolpolymerisate
AU2002243244A1 (en) High molecular weight polyolefin and catalyst and process for polymerising said polyolefin